- Home
- CMRC vs RLMD Comparison
CMRC vs RLMD Comparison
Compare CMRC & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMRC | RLMD |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.4M | 319.0M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | CMRC | RLMD |
|---|---|---|
| Price | $2.75 | $3.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $5.75 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 1.5M | 564.3K |
| Earning Date | 02-12-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $342,349,000.00 | N/A |
| Revenue This Year | $6.41 | N/A |
| Revenue Next Year | $4.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.83 | N/A |
| 52 Week Low | $2.41 | $0.24 |
| 52 Week High | $7.50 | $5.12 |
Technical Indicators
Market Signals| Indicator | CMRC | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 32.83 | 44.48 |
| Support Level | $2.41 | $3.71 |
| Resistance Level | $3.07 | $4.35 |
| Average True Range (ATR) | 0.20 | 0.32 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 41.86 | 44.36 |
Price Performance
Historical ComparisonAbout CMRC Commerce.com Inc.
Commerce.com Inc is engaged in offering Software-as-a-service (SaaS) e-commerce platform. The company's SaaS platform engages in the creation of online stores by delivering a combination of ease-of-use, enterprise functionality, and flexibility. It powers both the customers' branded ecommerce stores and their cross-channel connections to popular online marketplaces, social networks, and offline point-of-sale systems. The group operates in a single segment covering geographical areas of Americas-U.S.; Americas-other; EMEA; and APAC, of which majority of its revenue is generated from Americas-U.S.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.